Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 725

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 7
Chunk 725
---
2023 
  
    Net cash used in operating activities 
    $(241,159) 
    $(497,467)
  
    Net cash provided by investing activities 
     –  
     433,000 
  
    Net cash provided by financing activities 
     200,000  
     – 
  
    Net decrease in cash and cash equivalents 
    $(41,159) 
    $(64,467)

Cash Flows From Operating Activities 

Net cash used in operating activities for the year
ended December 31, 2024 consisted of our net loss of $921,983 offset by (i) non-cash interest expense of $73,533, (ii) non-cash share-based
compensation expense of $4,867, (iii) the accretion to redemption value on convertible notes of $1,446, and (iv) a net change in operating
assets and liabilities of $604,215 primarily due to an increase in accrued compensation of $582,741 and accounts payable of $16,387.

Net cash used in operating activities for the year
ended December 31, 2023 consisted of our net loss of $1,008,235 combined with a decrease in the fair value of the derivative liability
of $46,700 and a gain on redemption of preferred stock of Holocom of $433,000, which amounts were offset by (i) non-cash share-based compensation
expense of $21,935, (ii) non-cash interest expense of $73,333, (iii) the accretion to redemption value on convertible notes of $15,842,
and (iv) a net change in operating assets and liabilities of $879,358 primarily due to an increase in accrued compensation, accrued consulting,
and other accrued expenses of $877,067, in aggregate.

 35 

Cash Flows From Investing Activities

Net cash provided by investing activities for the
year ended December 31, 2023 consisted of proceeds received from our redemption of Holocom’s Series A Preferred Stock of $433,000.

Cash Flows From Financing Activities

Net cash provided by financing activities for the
year ended December 31, 2024 consisted of proceeds received from loan payable with an accredited investor totaling $200,000 (see Note
8 to the accompanying consolidated financial statements) and loan payable from Oncotelic totaling $70,000. The loan payable from Oncotelic
totaling $70,000 was paid in full